Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Novel cyclic peptide inhibits intercellular adhesion molecule-1-mediated cell aggregation.

J P Shannon1, M V Silva, D C Brown

  • 1Department of Pathology, University of New Mexico Health Science Center, Albuquerque, USA.

The Journal of Peptide Research : Official Journal of the American Peptide Society
|September 5, 2001
PubMed
Summary

Researchers developed a novel peptide, IP01, that inhibits ICAM-1-mediated cell adhesion, crucial for inflammatory responses. This small molecule offers potential for studying ICAM-1/LFA-1 interactions and developing new therapeutics.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Advancing outcome measure development and analytical approaches: Pain in Animals Workshop 2023.

Frontiers in pain research (Lausanne, Switzerland)·2025
Same author

Outcome assessment in veterinary pain studies: a pain in animals workshop (PAW) perspective.

Frontiers in pain research (Lausanne, Switzerland)·2025
Same author

Evaluation of the effect of exogenous melatonin on the placenta and inflammatory cytokines in rats submitted to chronic alcohol consumption.

Brazilian journal of biology = Revista brasleira de biologia·2025
Same author

Antifungal activity of terpenes isolated from the Brazilian Caatinga: a review.

Brazilian journal of biology = Revista brasleira de biologia·2023
Same author

Hydrolyzable tannins from Poincianella (Caesalpinia) microphylla fruits: Metabolite profiling and anti-Trichomonas vaginalis activity.

Food research international (Ottawa, Ont.)·2020
Same author

Anticryptococcal activity of hexane extract from Spondias tuberosa Arruda and associated cellular events.

Journal de mycologie medicale·2020

Area of Science:

  • Immunology
  • Biochemistry
  • Drug Discovery

Background:

  • Leukocyte adherence via ICAM-1/LFA-1 binding is vital for immune and inflammatory functions.
  • Inhibiting ICAM-1/LFA-1 interactions shows therapeutic potential in lymphoma and inflammatory diseases like arthritis and septic shock.

Purpose of the Study:

  • To develop and characterize a small peptide antagonist targeting ICAM-1-dependent cell aggregation.
  • To identify a novel molecule for studying ICAM-1 biology and developing therapeutics.

Main Methods:

  • Utilized phage display technology with a cyclic nonapeptide library to select for ICAM-1 binding peptides.
  • Synthesized and tested cyclic and linear IP01 peptides for their ability to inhibit ICAM-1-mediated cell aggregation.
  • Performed alanine scanning mutagenesis to identify key amino acids in IP01 responsible for inhibition.

Related Experiment Videos

  • Assessed IP01's effect on neutrophil adhesion under physiologic flow conditions.

    • Main Results:

    • Identified and selected the cyclic nonapeptide IP01 (C*LLRMRSIC*) for its potent inhibition of ICAM-1-dependent cell aggregation.
    • Cyclic and linear IP01 peptides inhibited ICAM-1-mediated aggregation at 1 mM, with cyclic IP01 showing an IC50 of ~970 µM.
    • IP01 did not affect aggregation mediated by ICAM-2 or ICAM-3, indicating specificity.
    • Key inhibitory residues in cyclic IP01 were identified as leucine 2, leucine 3, methionine 5, and arginine 6.
    • Cyclic IP01 effectively inhibited neutrophil firm adhesion to endothelium in a flow assay.

    Conclusions:

    • A novel small peptide, cyclic IP01, was developed that specifically inhibits ICAM-1-dependent cell adhesion.
    • IP01's mechanism of action is distinct from LFA-1, offering a unique therapeutic target.
    • IP01 serves as a valuable tool for investigating ICAM-1/LFA-1 biology and as a lead for small molecule drug development.